CHICAGO — In patients with type 2 diabetes and hypertension, empagliflozin significantly reduced BP in addition to improving blood glucose levels, according to research presented at the joint meeting ...
The EMPEROR-Preserved trial of empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) met its primary endpoint, according to top-line results released today, meaning a therapy with specific ...
Empagliflozin, compared with GLP-1RA, demonstrated improved cardiorenal outcomes among patients with type 2 diabetes. Empagliflozin vs cardioprotective glucagon-like peptide-1 receptor agonists ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In patients with type 2 diabetes and an ICD or CRT-D, ...
The advantage of empagliflozin, and the sodium glucose cotransporter 2 class generally, is that its unique mechanism expels excess glucose through the urine, thus offering the possibility of reducing ...
Cardiovascular disease and diabetes are often associated with each other, as many issues caused by diabetes promote heart issues. It stands to reason that perhaps a diabetes drug may be able to treat ...
Presentation of results at the European Association for the Study of Diabetes follows the announcement of topline results in August. For years, researchers and pharmaceutical leaders alike wondered if ...
Credit: Getty Images. The approval of empagliflozin for pediatric T2DM was based on data from the phase 3 DINAMO trial. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Its ...
"Heart failure is a devastating disease affecting hundreds of thousands of Canadians. Unfortunately the condition becomes progressively worse over time, leading to long and frequent hospitalizations ...
A new analysis of the EMPEROR-Preserved trial sheds light on the efficacy of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) in patients ...
Empagliflozin (Jardiance) reduced the risks of chronic kidney disease (CKD) progression and cardiovascular-related deaths in high-risk patients compared with placebo, the phase III EMPA-KIDNEY trial ...
The EMPA-REG OUTCOME trial is part of the new wave of cardiovascular (CV) outcome trials required by the US Food and Drug Administration (FDA) for all new diabetes drugs. Empagliflozin is in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback